Bortezomib, that contributed to clinical response of squamous cell carcinoma of the head and neck (SCCHN), antagonized cetuximab- and radiation-induced cytotoxicity, degradation of EGFR, and enhanced pro-survival signal pathway activation in SCCHN tumor biopsies and in the cell line UMSCC-1 [30]. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.